Healthcare entity

Curis

Company CRIS

Every one of those 1 sits in a single category, funding. Caleres is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window.

Last mentioned: Mar 20, 2026

Entity pulse

Recent coverage · Curis

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Curis

Every one of those 1 sits in a single category, funding. Caleres is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.3 for that window. Curis appears in 1 tracked Healthcare story from March 20, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Curis. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. ASH Annual Meeting

    Curis targets presentation of initial proof-of-concept data for the CLL study.

  2. Torrid Store Closures

    Target date for an additional 30 store closures by Torrid to reach savings goals.

  3. Q4 Earnings Release

    Curis, Torrid, Caleres, and Lands' End all report Q4 2025 results.

  4. PIPE Financing

    Curis secured initial $20.2M in PIPE proceeds to fund oncology pipeline development.

  5. Erivedge Wind-down

    Royalties from Erivedge began winding down, prompting the strategic sale to Oberland.

Stories mentioning Curis 1

Funding Neutral

Curis Secures Oncology Runway as Macro Headwinds Pressure Retail Margins

Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.

4 sources

Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)

Curis is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.